HENDERSON, Nev., Oct. 2, 2023 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21st at ESMO 2023, the annual congress of the European Society for Medical Oncology.
The webinar takes place on Thursday, October 26th at 10:30 AM U.S. Eastern Time and will include updates from Volition’s Dr. Jake Micallef (Chief Scientific Officer) and Mr. Gael Forterre (Chief Commercial Officer), and Dr Andrew Retter, a leading UK-based Haematologist and Medical Consultant at Volition.
Dr. Jake Micallef, Chief Scientific Officer at Volition, said:
“Our upcoming webinar is a timely opportunity to talk through exciting breakthrough data in our Capture pillar, regarding what we believe to be an entirely new method for the early detection of cancer. We will provide stakeholders with deeper insights into the data we are presenting at ESMO 2023, and outline our next steps towards commercialization.”
The panel and Q&A event is being hosted by Ms. Soo Romanoff, Managing Director of Healthcare at Edison Group.
Event Details:
Title: Volition Data Insights Webinar
Date: Thursday, October 26, 2023
Time: 10:30 AM U.S Eastern
Register at: Edison Webinar
To register for Volition’s data insights webinar click HERE. The event will be recorded and available afterward on-demand.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s technology go to: www.volition.com.
About Volition
Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
For more information about Volition’s Nu.Q® technology go to: www.volition.com
The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. This website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition’s estimated market opportunity, the effectiveness of Volition’s blood-based diagnostic, prognostic and disease monitoring tests, and Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
Contact Details:
Louise Batchelor / Debra Daglish
Volition
mediarelations@volition.com
+44 (0)7557 774620
View original content:https://www.prnewswire.com/news-releases/volition-to-reveal-new-cancer-detection-method-insights-at-upcoming-webinar-301944261.html
SOURCE VolitionRx Limited
